Alumis Psoriasis Treatment Shows Leading Skin Clearance Rates - Alumis (NASDAQ:ALMS)

Alumis releases long-term data for psoriasis drug envudeucitinib, boasting top skin clearance rates ahead of a Q4 FDA filing with FDA.

Raccontata dabenzinga.com